Values First Advisors Inc. Sells 636 Shares of argenx SE (NASDAQ:ARGX)

Values First Advisors Inc. reduced its stake in argenx SE (NASDAQ:ARGX) by 34.8% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,194 shares of the company’s stock after selling 636 shares during the period. Values First Advisors Inc.’s holdings in argenx were worth $647,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the stock. Price T Rowe Associates Inc. MD boosted its holdings in shares of argenx by 49.8% in the first quarter. Price T Rowe Associates Inc. MD now owns 5,504,506 shares of the company’s stock worth $2,167,235,000 after acquiring an additional 1,830,651 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of argenx by 24.8% in the first quarter. Janus Henderson Group PLC now owns 2,216,648 shares of the company’s stock worth $872,690,000 after acquiring an additional 439,889 shares during the period. Avoro Capital Advisors LLC boosted its holdings in shares of argenx by 0.3% in the first quarter. Avoro Capital Advisors LLC now owns 1,238,467 shares of the company’s stock worth $487,609,000 after acquiring an additional 3,900 shares during the period. Clearbridge Investments LLC boosted its holdings in shares of argenx by 3.6% in the second quarter. Clearbridge Investments LLC now owns 617,466 shares of the company’s stock worth $265,535,000 after acquiring an additional 21,189 shares during the period. Finally, Sei Investments Co. boosted its holdings in shares of argenx by 15.2% in the second quarter. Sei Investments Co. now owns 381,544 shares of the company’s stock worth $164,079,000 after acquiring an additional 50,477 shares during the period. 60.32% of the stock is owned by institutional investors.

argenx Price Performance

NASDAQ ARGX opened at $551.15 on Friday. The stock has a market capitalization of $32.76 billion, a PE ratio of -97.38 and a beta of 0.63. argenx SE has a 1 year low of $327.73 and a 1 year high of $571.97. The business’s 50-day moving average is $534.21 and its 200 day moving average is $458.10.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, July 25th. The company reported $0.45 earnings per share for the quarter, beating the consensus estimate of ($0.89) by $1.34. The business had revenue of $489.43 million for the quarter, compared to analysts’ expectations of $436.66 million. argenx had a negative return on equity of 7.33% and a negative net margin of 12.31%. During the same period in the previous year, the firm posted ($1.69) EPS. As a group, equities research analysts anticipate that argenx SE will post -0.37 earnings per share for the current year.

Analysts Set New Price Targets

ARGX has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. increased their price objective on argenx from $500.00 to $640.00 and gave the stock an “overweight” rating in a research report on Friday, August 23rd. HC Wainwright increased their price objective on argenx from $504.00 to $533.00 and gave the stock a “buy” rating in a research report on Friday, July 26th. Raymond James reiterated a “strong-buy” rating and issued a $605.00 price objective on shares of argenx in a research report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft downgraded argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. Finally, Robert W. Baird raised their price target on argenx from $490.00 to $515.00 and gave the company an “outperform” rating in a research report on Monday, July 29th. Four investment analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, argenx currently has an average rating of “Moderate Buy” and an average price target of $550.44.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.